AAPharmaSyn has engaged with multiple early-stage projects to help clients develop novel carbohydrate containing therapeutics. We are intimately familiar with the challenges in both synthesis and characterization of novel carbohydrates. We made a material investment of effort and capital in building a superior competence in this field.

Carbohydrates are one of the most abundant and ubiquitous class of biomolecules found in all known living organisms either free or covalently linked to other structures, forming glycoproteins, proteoglycans, or glycolipids. Their importance has been widely recognized due to their functional roles in metabolism and energy storage. The important biological roles of carbohydrate-mediated processes are currently pursued as targets of drug development by both public and private entities.

Discovery of the First Antibiotic Containing Saccharides

Nucleoside Analogues were Approved for the Treatment of Anti-viral and Anti-tumors

Discovery of Oligosaccharide as Anti- infective Agents

Fondaparinux was Approved for the prevention of Throm- boembolic Events

Nelarabine was Approved for The Treatment of Leukemia

Sugammadex was Approvedfor the Treatment of Nervous System Diseases

Dapagliflozin Was Approvedas the First SGLT2 Inhibitorfor the Treatment Of T2DM

Plazomicin was Approved asAminoglycoside for the Treatmentof serious bacterial infections

Remdesivir was Approved for treatment of COVID-19

Development of Sialic Acid Mimetics as High-Affinity Ligands for Sialic Acid Binding Immunoglobulin-Like Lectin 2

Mimetics:

chemical

Natural-Sialoside:

  • R2: Galactose-glycan
  • R3: H
  • R4: OH
  • R5: AC
  • R9: OH
carbohydrate